4Q Revenues: $442 million (+38%)
4Q Loss: $19 million (earnings of $81 million in 4Q12)
FY Revenues: $1.6 billion (+37%)
FY Earnings: $253 million (-1%)
Comments: Sales of the company's sole commercial product, Soliris, continued to grow as it added new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion took a $153 million charge during FY13 in connection with centralizing certain business operations, impairment of intangible assets, expenses from license agreements, and an intellectual property settlement; $129 million of that was incurred in 4Q13, leading to a net loss.